Sign up to save your podcasts
Or
Share SELECT TRIAL: Semaglutide, Central Fat, and Cardioprotection 🧪🏹🛡️
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
SELECT TRIAL: Semaglutide, Central Fat, and Cardioprotection 🧪🏹🛡️
🫀📉 Published in The Lancet (Oct 22, 2025): SELECT trial investigators report that semaglutide reduced MACE by 20% in patients with obesity but without diabetes—independent of weight loss. Waist circumference, not weight, tracked with outcomes, yet explained only 33% of the benefit. This landmark analysis redefines GLP-1RAs as disease-modifying agents, not just weight-loss drugs.
👉 Read here: https://doi.org/10.1016/S0140-6736(25)01375-3
#SELECTTrial #Semaglutide #Cardiovascular #Obesity #GLP1RA #TheLancet
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
🫀📉 Published in The Lancet (Oct 22, 2025): SELECT trial investigators report that semaglutide reduced MACE by 20% in patients with obesity but without diabetes—independent of weight loss. Waist circumference, not weight, tracked with outcomes, yet explained only 33% of the benefit. This landmark analysis redefines GLP-1RAs as disease-modifying agents, not just weight-loss drugs.
👉 Read here: https://doi.org/10.1016/S0140-6736(25)01375-3
#SELECTTrial #Semaglutide #Cardiovascular #Obesity #GLP1RA #TheLancet
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
892 Listeners
The Curbsiders Internal Medicine Podcast
3,371 Listeners
The Mel Robbins Podcast
21,362 Listeners